Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma.
Nath K, Law SC, Sabdia MB, Gunawardana J, de Long LM, Sester D, Shanavas M, Tsang H, Tobin JWD, Halliday SJ, Hernandez A, Cross D, Bird RJ, Jain S, Keane C, Talaulikar D, Trotman J, Law P, Gandhi MK. Nath K, et al. Among authors: trotman j. Blood Adv. 2021 Jun 22;5(12):2644-2649. doi: 10.1182/bloodadvances.2020004051. Blood Adv. 2021. PMID: 34156439 Free PMC article.
Positron emission tomography-computed tomography (PET-CT) after induction therapy is highly predictive of patient outcome in follicular lymphoma: analysis of PET-CT in a subset of PRIMA trial participants.
Trotman J, Fournier M, Lamy T, Seymour JF, Sonet A, Janikova A, Shpilberg O, Gyan E, Tilly H, Estell J, Forsyth C, Decaudin D, Fabiani B, Gabarre J, Salles B, Van Den Neste E, Canioni D, Garin E, Fulham M, Vander Borght T, Salles G. Trotman J, et al. J Clin Oncol. 2011 Aug 10;29(23):3194-200. doi: 10.1200/JCO.2011.35.0736. Epub 2011 Jul 11. J Clin Oncol. 2011. PMID: 21747087
PET-CT for staging and early response: results from the Response-Adapted Therapy in Advanced Hodgkin Lymphoma study.
Barrington SF, Kirkwood AA, Franceschetto A, Fulham MJ, Roberts TH, Almquist H, Brun E, Hjorthaug K, Viney ZN, Pike LC, Federico M, Luminari S, Radford J, Trotman J, Fosså A, Berkahn L, Molin D, D'Amore F, Sinclair DA, Smith P, O'Doherty MJ, Stevens L, Johnson PW. Barrington SF, et al. Among authors: trotman j. Blood. 2016 Mar 24;127(12):1531-8. doi: 10.1182/blood-2015-11-679407. Epub 2016 Jan 8. Blood. 2016. PMID: 26747247 Free article.
Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.
Talaulikar D, Tam CS, Joshua D, Ho JP, Szer J, Quach H, Spencer A, Harrison S, Mollee P, Roberts AW, Horvath N, Lee C, Zannettino A, Brown R, Augustson B, Jaksic W, Gibson J, Kalff A, Johnston A, Trotman J, Kalro A, Grigoriadis G, Ward C, Prince HM. Talaulikar D, et al. Among authors: trotman j. Intern Med J. 2017 Jan;47(1):35-49. doi: 10.1111/imj.13311. Intern Med J. 2017. PMID: 28076910
Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
Hertzberg M, Gandhi MK, Trotman J, Butcher B, Taper J, Johnston A, Gill D, Ho SJ, Cull G, Fay K, Chong G, Grigg A, Lewis ID, Milliken S, Renwick W, Hahn U, Filshie R, Kannourakis G, Watson AM, Warburton P, Wirth A, Seymour JF, Hofman MS, Hicks RJ; Australasian Leukaemia Lymphoma Group (ALLG). Hertzberg M, et al. Among authors: trotman j. Haematologica. 2017 Feb;102(2):356-363. doi: 10.3324/haematol.2016.154039. Epub 2016 Nov 10. Haematologica. 2017. PMID: 28143954 Free PMC article. Clinical Trial.
Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study.
Cottereau AS, Versari A, Luminari S, Dupuis J, Chartier L, Casasnovas RO, Berriolo-Riedinger A, Menga M, Haioun C, Tilly H, Tarantino V, Federico M, Salles G, Trotman J, Meignan M. Cottereau AS, et al. Among authors: trotman j. Blood. 2018 May 31;131(22):2449-2453. doi: 10.1182/blood-2017-11-816298. Epub 2018 Mar 20. Blood. 2018. PMID: 29559480 Free article. Clinical Trial.
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL.
Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D, Harrup R, Johnston PB, Marlton P, Munoz J, Seymour JF, Simpson D, Tedeschi A, Elstrom R, Yu Y, Tang Z, Han L, Huang J, Novotny W, Wang L, Roberts AW. Tam CS, et al. Among authors: trotman j. Blood. 2019 Sep 12;134(11):851-859. doi: 10.1182/blood.2019001160. Epub 2019 Jul 24. Blood. 2019. PMID: 31340982 Free PMC article. Clinical Trial.
High total metabolic tumor volume at baseline predicts survival independent of response to therapy.
Vercellino L, Cottereau AS, Casasnovas O, Tilly H, Feugier P, Chartier L, Fruchart C, Roulin L, Oberic L, Pica GM, Ribrag V, Abraham J, Simon M, Gonzalez H, Bouabdallah R, Fitoussi O, Sebban C, López-Guillermo A, Sanhes L, Morschhauser F, Trotman J, Corront B, Choufi B, Snauwaert S, Godmer P, Briere J, Salles G, Gaulard P, Meignan M, Thieblemont C. Vercellino L, et al. Among authors: trotman j. Blood. 2020 Apr 16;135(16):1396-1405. doi: 10.1182/blood.2019003526. Blood. 2020. PMID: 31978225 Free PMC article. Clinical Trial.
179 results